Institut Català de la Salut
[Søreide K] Department of Gastrointestinal Surgery, HPB Unit, Stavanger University Hospital, Stavanger, Norway. Department of Clinical Medicine, University of Bergen, Bergen, Norway. Division of Surgery and Oncology, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden. [Dopazo C] Servei de Cirurgia Hepatobiliopancreàtica i Trasplantaments, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Berrevoet F] Department of General and HPB Surgery and Liver Transplantation, Ghent University Hospital, Ghent, Belgium. [Carrion-Alvarez L] Department of General Surgery, HPB Unit, Fuenlabrada University Hospital, Madrid, Spain. [Diaz-Nieto R] Hepatobiliary Surgery Unit, Liverpool University Hospital, Liverpool, UK. [Andersson B] Department of Clinical Sciences Lund, Surgery, Lund University and Skåne University Hospital, Lund, Sweden
Vall d'Hebron Barcelona Hospital Campus
2025-05-30T06:36:06Z
2025-05-30T06:36:06Z
2024
2025-06
Bile duct cancer; Chemotherapy; Cholangiocarinoma
Càncer de les conducte biliar; Quimioteràpia; Colangiocarinoma
Cáncer de las vías biliares; Quimioterapia; Colangiocarcinoma
Background Biliary tract cancers comprise a heterogeneous collection of malignancies usually described as cholangiocarcinoma of the intra- or extrahepatic bile duct, including perihilar cholangiocarcinoma and gallbladder cancer. Methods A review of pertinent parts of the ESSO core curriculum for the UEMS diploma targets (Fellowships exam, EBSQ), based on updated and available guidelines for diagnosis, surgical treatment and oncological management of cholangiocarcinoma. Results Following the outline from the ESSO core curriculum we present the epidemiology and risk factors for cholangiocarcinoma, as well as the rationale for the current diagnosis, staging, (neo-)adjuvant treatment, surgical management, and short- and long-term outcomes. The available guidelines and consensus reports (i.e. NCCN, BGS and ESMO guidelines) are referred to. Recognition of biliary tract cancers as separate entities of the intrahepatic biliary ducts, the perihilar and distal bile duct as well as the gallbladder is important for proper management, as they each provide distinct clinical, molecular and treatment profiles to consider. Conclusion Core competencies in knowledge to the diagnosis, management and outcomes of biliary tract cancers are presented.
Artículo
Versión publicada
Inglés
Conductes biliars - Càncer - Tractament; Conductes biliars - Càncer - Diagnòstic; Vesícula biliar - Càncer - Tractament; Vesícula biliar - Càncer - Diagnòstic; DISEASES::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Biliary Tract Neoplasms::Bile Duct Neoplasms; Other subheadings::Other subheadings::/therapy; DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Glandular and Epithelial::Carcinoma::Adenocarcinoma::Cholangiocarcinoma; DISEASES::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Biliary Tract Neoplasms::Gallbladder Neoplasms; ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias del tracto biliar::neoplasias de los conductos biliares; Otros calificadores::Otros calificadores::/terapia; ENFERMEDADES::neoplasias::neoplasias por tipo histológico::neoplasias glandulares y epiteliales::carcinoma::adenocarcinoma::colangiocarcinoma; ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias del tracto biliar::neoplasias de la vesícula biliar
Elsevier
European Journal of Surgical Oncology;51(6)
https://doi.org/10.1016/j.ejso.2024.108489
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
Articles científics - VHIR [1655]